Investing in Microcap Biotech Stocks


Investing in microcap biotech stocks is a smart way to grow your investment portfolio. With these companies, you’ll have the opportunity to own a small share of a company that is developing a promising technology. It’s not a risk-free investment, but with a little forethought, you can build a portfolio that is profitable.


Medicenna Therapeutics Corporation (NASDAQ: MTX) is a microcap biotech stock in the immuno-oncology space. Its principal business activity is the development of engineered interleukins, or superkines, as well as super-sized versions of IL-4 and IL-13. It also has a solid drug candidate pipeline, including MDNA55 for recurrent glioblastoma multiforme and MDNA209 for autoimmune diseases. Its stock has not been a winner on the TSX, but there are some reasons to keep an eye on it.

Medicenna isn’t the only company making a splash in the biotech arena. Another notable player is Anthera Pharmaceuticals, Inc., which saw its shares tumble on the news of a failed Phase 3 CHABLIS-SC1 trial.

Medicenna is also making waves in the medical technology arena with its novel drug that conjugates IL-4 and IL-13. The drug is a small molecule that kills cancer cells by introducing a toxin into the cells. The company also has a promising Phase II trial underway.

Other tidbits to be found at Medicenna include a pipeline of immunotherapy candidates for both solid tumors and autoimmune diseases. Its most notable product is a selective IL-4 derivative, which may one day become a treatment for certain types of breast cancer. It also has a slew of clinical trials slated for later this year. The company is also in the process of restructuring its staff, which should reduce cash burn.

Medicenna isn’t necessarily the best microcap biotech stock on the TSX, but it’s not a bad choice.

Actinium Pharmaceuticals

Despite its small size, Actinium Pharmaceuticals is a biotechnology stock that has been making some impressive advances on all fronts this year. The company has been focusing on filling gaps left by traditional cancer therapies. The company has two promising franchises that have applications across multiple cancer indications.

Actinium Pharmaceuticals is developing Antibody Radiation-Conjugates (ARADs), a class of drugs that combine the targeting ability of antibodies with the cell killing ability of radiation. ARADs are targeted at cancer cells and can be guided to specific immune cells to maximize the effectiveness of treatment.

ARADs are designed to attack specific immune cells, preventing them from attacking the body and reducing the chances of disease. The technology is part of Actinium Pharmaceuticals’ AWE Technology platform. This platform is in the early stages of development, but the company is collaborating with other biotech innovators to help accelerate its advancements.

Iomab is another promising drug developed by Actinium. It has the potential to alleviate the adverse effects of CAR-T/Gene-Tx therapies. The company has high hopes for Iomab-B, which is being tested in a phase 3 trial. The trial will determine whether Iomab-B is safe and effective for patients with AML.

Actinium Pharmaceuticals recently announced a licensing agreement with Immedica Pharma AB. Immedica AB is a European independent pharmaceutical company that specializes in developing treatments for rare diseases. Immedica AB also has a strong presence in the Middle East, which may provide the company with a valuable platform for commercialization in that region.

AudioCodes Ltd.

Founded in 1992, AudioCodes is an Israeli brew that focuses on the design, development and marketing of converged voice, video, data and mobility solutions for enterprise customers and service providers. It is also a provider of unified messaging and contact center solutions. Its product portfolio includes communications software, value-added applications, and IP phones. AudioCodes has a strong foothold in the U.S., Europe, and the Middle East, where it serves customers across the globe. The company has a strong emphasis on customer engagement and is a major player in the Microsoft 365 and Lync family of products.

The company’s products and services include a comprehensive suite of contact center solutions and unified communications (UC) applications, and a robust set of VoIP and video products, including enterprise class SBCs, VoIP network routing solutions, and voice over IP (VOIP) communication boards. The company’s latest product, the RX50, delivers an impressive audio quality in any meeting space, while enabling centralized control over session routing decisions.

The company’s high-end products are complemented by a robust portfolio of professional services and managed services. The company is a leading innovator in the communications software industry, and its products are used in enterprise networks across the globe. The company’s products and solutions are aimed at enhancing the customer experience, while enhancing the productivity of users and managers. Among the company’s product lines are the telephony juggernauts, including the One Voice Operations Center (OVOC), the MVoice UC and contact center solutions, and the VoiceAI business line.


Among the best small cap biotech stocks to invest in in 2022 are Dynavax Technologies Corp. This company develops immune-oncology therapeutics. The company’s products treat cancer, shingles, chronic inflammatory diseases, and infectious diseases.

Dynavax is a fully-integrated clinical-stage biopharmaceutical company. It has a strong financial position and is ready for long-term growth. In addition, the company’s product pipeline is robust and includes a hepatitis B vaccine. The company’s immunotherapy products are currently in Phase 1/2 studies.

Dynavax’s lead product, HEPLISAV-B, prevents infection caused by all known subtypes of the hepatitis B virus in adults. In November 2017, the company received FDA approval for this drug. Its second product, DV281, is in Phase 1 development.

Biotech companies are developing new treatments for serious diseases such as cancer, Alzheimer’s, and Parkinson’s. They also manufacture lab equipment and diagnostic tools. They are the future of modern medicine. However, there are some risks with this sector. In June, biotech stocks dropped to a six-year low. Despite this decline, the stock has steadily recovered.

Biotech companies are leveraging the body’s adaptive immune responses to develop new vaccines and therapeutics. A number of biotech companies also sell their technology to pharmaceutical companies. This can help them to mass-produce new drug technologies.

One of the biggest investors in Dynavax is Bain Capital Life Sciences Investors, LLC. Other large investors include Chicago Capital, LLC, BlackRock Inc., and Vanguard Group Inc.

Wasatch Micro Cap Value

Choosing the best mutual fund for your portfolio can be a daunting task. But with a little research, you can find the best of the best. With the help of a guide, you can make the right choice for you and your family. If you’re looking for a quality fund that will take care of your money while ensuring your investment is safe and sound, then the Wasatch Micro Cap Value Fund should be on your short list. The fund boasts a whopping 54% distribution. The best part? All the micro cap stocks in the fund have a market cap of under $10 billion. This may not sound like much, but when you have over $90 billion in invested capital, it can be a big deal.

The Wasatch Micro Cap Value Fund’s small but impressive portfolio may be yours for less than half a penny a day. With an average annual cost of just over $700, the Fund is a steal. The Fund is managed by Ken Korngiebel, who has over twenty years of experience at the helm of the venniture. The fund’s seasoned portfolio manager has a track record of producing outperformance. The aforementioned fund’s rabid investors are a testament to his talents. So, if you’re in the market for a quality mutual fund, make the Wasatch Micro Cap Value Fund your new best friend. The fund is managed by one of the oldest names in the industry.

Walthausen Small Cap Value

Investing in Walthausen Small Cap Value (WSCVX) has proven to be a winning proposition for the past few years. A solid portfolio mix of high growth and high yield stocks has rewarded investors with a stellar rate of return, albeit at the cost of capital. While the stock has seen a number of upticks and downticks, its performance has never been compromised. As such, it is a worthy addition to any savvy investor’s portfolio.

One of the more notable achievements of the company’s management is its track record of nabbing the best picks from the competition. While it isn’t a secret that Walthausen Small Cap Value (WSCVX) does a brisk business in the biotech space, its recent acquisition of biotech titan Iovance Biotherapeutics (IVA) has put the company on the map in more ways than one. Having acquired Iovance for a mere $2.5 billion, the company’s stock has gained a new found respect in the coveted biotech sector.


Please enter your comment!
Please enter your name here